221 related articles for article (PubMed ID: 28884745)
21. Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
De Rienzo A; Archer MA; Yeap BY; Dao N; Sciaranghella D; Sideris AC; Zheng Y; Holman AG; Wang YE; Dal Cin PS; Fletcher JA; Rubio R; Croft L; Quackenbush J; Sugarbaker PE; Munir KJ; Battilana JR; Gustafson CE; Chirieac LR; Ching SM; Wong J; Tay LC; Rudd S; Hercus R; Sugarbaker DJ; Richards WG; Bueno R
Cancer Res; 2016 Jan; 76(2):319-28. PubMed ID: 26554828
[TBL] [Abstract][Full Text] [Related]
22. Fluorescence in situ hybridization (FISH) provides estimates of minute and interstitial BAP1, CDKN2A, and NF2 gene deletions in peritoneal mesothelioma.
Brich S; Bozzi F; Perrone F; Tamborini E; Cabras AD; Deraco M; Stacchiotti S; Dagrada GP; Pilotti S
Mod Pathol; 2020 Feb; 33(2):217-227. PubMed ID: 31570769
[TBL] [Abstract][Full Text] [Related]
23. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
[TBL] [Abstract][Full Text] [Related]
24. Two Different Serum MiRNA Signatures Correlate with the Clinical Outcome and Histological Subtype in Pleural Malignant Mesothelioma Patients.
Lamberti M; Capasso R; Lombardi A; Di Domenico M; Fiorelli A; Feola A; Perna AF; Santini M; Caraglia M; Ingrosso D
PLoS One; 2015; 10(8):e0135331. PubMed ID: 26262875
[TBL] [Abstract][Full Text] [Related]
25. Testing for BAP1 loss and CDKN2A/p16 homozygous deletion improves the accurate diagnosis of mesothelial proliferations in effusion cytology.
Chevrier M; Monaco SE; Jerome JA; Galateau-Salle F; Churg A; Dacic S
Cancer Cytopathol; 2020 Dec; 128(12):939-947. PubMed ID: 32678499
[TBL] [Abstract][Full Text] [Related]
26. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
27. Clinical and pathologic predictors of clinical outcome of malignant pleural mesothelioma.
Berardi R; Fiordoliva I; De Lisa M; Ballatore Z; Caramanti M; Morgese F; Savini A; Rinaldi S; Torniai M; Tiberi M; Ferrini C; Onofri A; Cascinu S
Tumori; 2016; 102(2):190-5. PubMed ID: 26893272
[TBL] [Abstract][Full Text] [Related]
28. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
[TBL] [Abstract][Full Text] [Related]
29. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
[TBL] [Abstract][Full Text] [Related]
30. Amount of Epithelioid Differentiation Is a Predictor of Survival in Malignant Pleural Mesothelioma.
Vigneswaran WT; Kircheva DY; Ananthanarayanan V; Watson S; Arif Q; Celauro AD; Kindler HL; Husain AN
Ann Thorac Surg; 2017 Mar; 103(3):962-966. PubMed ID: 27765170
[TBL] [Abstract][Full Text] [Related]
31. A new prognostic index for overall survival in malignant pleural mesothelioma: the rPHS (regimen, PS, histology or stage) index.
Kataoka Y; Yamamoto Y; Otsuki T; Shinomiya M; Terada T; Fukuma S; Yamazaki S; Hirabayashi M; Nakano T; Fukuhara S
Jpn J Clin Oncol; 2015 Jun; 45(6):562-8. PubMed ID: 25838292
[TBL] [Abstract][Full Text] [Related]
32. Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
Thapa B; Walkiewicz M; Murone C; Asadi K; Deb S; Barnett S; Knight S; Mitchell P; Liew D; Watkins DN; John T
Pathology; 2016 Dec; 48(7):660-665. PubMed ID: 27780599
[TBL] [Abstract][Full Text] [Related]
33. Sarcomatoid mesothelioma diagnosed in a patient with mesothelioma in situ: a case report on morphologic differences after 9-month interval with details analysis of cytology in early-stage mesothelioma.
Yoshida M; Jimbo N; Tsukamoto R; Itoh T; Kawahara K; Mitsui S; Tanaka Y; Maniwa Y
Diagn Pathol; 2023 Nov; 18(1):126. PubMed ID: 38017544
[TBL] [Abstract][Full Text] [Related]
34. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array.
Chirac P; Maillet D; Leprêtre F; Isaac S; Glehen O; Figeac M; Villeneuve L; Péron J; Gibson F; Galateau-Sallé F; Gilly FN; Brevet M
Hum Pathol; 2016 Sep; 55():72-82. PubMed ID: 27184482
[TBL] [Abstract][Full Text] [Related]
35. A Subset of Malignant Mesotheliomas in Young Adults Are Associated With Recurrent EWSR1/FUS-ATF1 Fusions.
Desmeules P; Joubert P; Zhang L; Al-Ahmadie HA; Fletcher CD; Vakiani E; Delair DF; Rekhtman N; Ladanyi M; Travis WD; Antonescu CR
Am J Surg Pathol; 2017 Jul; 41(7):980-988. PubMed ID: 28505004
[TBL] [Abstract][Full Text] [Related]
36. Sarcomatoid Mesothelioma: A CDKN2A molecular analysis of 53 cases with immunohistochemical correlation with BAP1.
Zaleski M; Kalhor N; Fujimoto J; Wistuba I; Moran CA
Pathol Res Pract; 2020 Dec; 216(12):153267. PubMed ID: 33176261
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
[TBL] [Abstract][Full Text] [Related]
38. Analysis of early pleural fluid samples in patients with mesothelioma: A case series exploration of morphology, BAP1, and CDKN2A status with implications for the concept of mesothelioma in situ in cytology.
Louw A; van Vliet C; Peverall J; Colkers S; Acott N; Creaney J; Lee YCG; Chai SM
Cancer Cytopathol; 2022 May; 130(5):352-362. PubMed ID: 35143119
[TBL] [Abstract][Full Text] [Related]
39. Prognostic factors affecting survival in malignant pleural mesothelioma: analysis of 125 subjects.
Komurcuoglu B; Cirak AK; Kirakli SC; Polat G; Yucel N; Usluer O; Erer O; Balci G; Gayaf M; Guldaval F; Aktogu S; Guclu S; Ozsoz A; Halilcolar H
Tumori; 2014; 100(1):55-9. PubMed ID: 24675492
[TBL] [Abstract][Full Text] [Related]
40. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations.
Sneddon S; Dick I; Lee YCG; Musk AWB; Patch AM; Pearson JV; Waddell N; Allcock RJN; Holt RA; Robinson BWS; Creaney J
Lung Cancer; 2018 May; 119():64-70. PubMed ID: 29656754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
